About VIA

VIA is committed to being a leading biotechnology company focused on discovering, developing and commercializing novel drugs for the treatment of cardiovascular and metabolic disease.

• Home
• About VIA
  • Management Team
  • Board of Directors
  • Advisors
  • Partnering
• Product Pipeline
  • Metabolic Drug Candidates
  • VIA-2291
• About Cardiometabolic Diseases
• Scientific Publications
• Investor Relations
  • News
  • Media
• Newsroom
  • Press Releases
• Careers
  • Job Opportunities
  • Benefits
• Contact Us

Recent Corporate Milestones

• Positive Phase 2 data from ACS study and MDCT sub-study published in Circulation: Cardiovascular Imaging
  Read more
• Positive Phase 2 data from MDCT sub-study presented at AHA ATVB, Q2 2009
• VIA secures $10.0 million in financing, Q1 2009
• New patent issued on VIA-2291, Q1 2009
• Pipeline expanded with THR Beta Agonist and DGAT1 assets, Q4 2008